Natera (NASDAQ:NTRA) Price Target Raised to $200.00

Natera (NASDAQ:NTRA) had its target price hoisted by Guggenheim from $170.00 to $200.00 in a research report report published on Friday morning,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Several other equities research analysts have also weighed in on NTRA. Piper Sandler increased their target price on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. Sanford C. Bernstein raised their price objective on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, January 10th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. JPMorgan Chase & Co. lifted their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Finally, Canaccord Genuity Group boosted their price objective on Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, January 3rd. One investment analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $160.63.

Natera Stock Down 6.0 %

NASDAQ:NTRA opened at $158.36 on Friday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera has a 12-month low of $62.96 and a 12-month high of $183.00. The stock’s fifty day simple moving average is $164.00 and its 200-day simple moving average is $134.44. The firm has a market capitalization of $20.91 billion, a P/E ratio of -89.98 and a beta of 1.65.

Natera (NASDAQ:NTRA) last issued its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue was up 63.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.95) earnings per share. Equities research analysts expect that Natera will post -1.61 earnings per share for the current year.

Insider Buying and Selling at Natera

In other news, insider John Fesko sold 669 shares of Natera stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $159.60, for a total value of $106,772.40. Following the completion of the transaction, the insider now owns 114,142 shares of the company’s stock, valued at $18,217,063.20. This trade represents a 0.58 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Solomon Moshkevich sold 256 shares of the business’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $120.07, for a total transaction of $30,737.92. Following the transaction, the insider now owns 111,891 shares in the company, valued at $13,434,752.37. This represents a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 121,092 shares of company stock worth $19,765,830 over the last ninety days. 7.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Natera

A number of hedge funds have recently made changes to their positions in the business. Itau Unibanco Holding S.A. bought a new stake in Natera in the 2nd quarter valued at $28,000. Quarry LP increased its holdings in shares of Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares during the last quarter. Versant Capital Management Inc raised its position in shares of Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 166 shares during the period. Covestor Ltd lifted its stake in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after buying an additional 106 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.